Clearpoint Neuro, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on May 26, 2022, regarding events occurring at the Company's 2022 Annual Meeting of Stockholders held on May 24, 2022. Clearpoint Neuro, Inc. is a Delaware corporation with its principal executive offices in Solana Beach, California, and its common stock trades on the Nasdaq Capital Market under the symbol "CLPT."
Key Financial Metrics
This filing is a current report regarding corporate governance and capital structure changes. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial performance metrics.
Material Changes
The primary material change reported is the reduction of the Company's authorized common stock. Stockholders approved an amendment to the Amended and Restated Certificate of Incorporation to reduce the number of authorized shares from 200,000,000 to 80,000,000. No other changes to the certificate of incorporation were made.
Corporate Actions and Voting Results
Stockholders voted on and approved five proposals at the Annual Meeting:
- Election of Directors: Eight directors were elected to serve until the 2023 annual meeting. All nominees received significant "For" votes, with broker non-votes totaling 6,049,948 for each nominee.
- Ratification of Auditors: Stockholders ratified the appointment of Cherry Bekaert LLP as the independent registered public accounting firm for the year ending December 31, 2022.
- Executive Compensation: Stockholders provided advisory approval of executive compensation.
- Incentive Compensation Plan: Stockholders approved the Fourth Amended and Restated 2013 Incentive Compensation Plan.
- Amendment to Certificate of Incorporation: Stockholders approved the reduction of authorized shares as noted above.
Investor Verification Checklist
- Verify the impact of the authorized share reduction (from 200 million to 80 million) on future capital raising capabilities and potential dilution.
- Review the full text of the Certificate of Amendment filed as Exhibit 3.1 for specific legal terms.
- Confirm the details of the Fourth Amended and Restated 2013 Incentive Compensation Plan (Exhibit 10.1) to understand equity grant limits and terms.
- Check subsequent filings for the Company's actual financial performance, as this 8-K contains no financial data.